We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter (BAX) to Enhance Its Portfolio With Latest Partnership
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) recently announced a long-term strategic partnership with Digital Diagnostics to advance diabetic retinopathy detection. The tie-up is aimed at helping front-line care providers deliver better quality of care and improve care outcomes.
It is worth mentioning that Baxter’s latest tie-up with the pioneering autonomous artificial intelligence (“AI”) diagnostics company includes plans to offer Digital Diagnostics’ IDx-DR autonomous AI software as a diagnostic service combined with the Welch Allyn RetinaVue 700 Imager (currently available for use in the United States). Notably, the agreement between Baxter and Digital Diagnostics is exclusive in the United States and non-exclusive outside.
The Welch Allyn product family became a part of Baxter's global medical technology portfolio following the latter’s acquisition of Hill-Rom in late 2021. The FDA clearance of IDx-DR with the RetinaVue 700 Imager is expected by early 2023.
The latest partnership is expected to significantly solidify Baxter’s global foothold in the connected care diagnostics portfolio.
Rationale Behind the Collaboration
Per current estimates (as mentioned in the press release), only around 15% of the diabetic patient pool receive the recommended annual diabetic eye exam. Also, access to effective diagnostic services is a hindrance, particularly in rural or underserved areas. This, in turn, leaves many with undiagnosed and untreated levels of disease, and a higher risk of consequent visual loss and blindness, as is recognized by the HEDIS/MIPS requirements for the diabetic eye exam. Hence, Digital Diagnostics created the autonomous AI diagnostic system — IDx-DR — for the detection of diabetic retinopathy (including diabetic macular edema) at the point of care.
Per Baxter’s management, the integration of AI within its devices is expected to provide a clear view of patient status to the primary care givers, thereby detecting information critical for treatment plans. The company believes that the partnership with Digital Diagnostics is integral in expanding its connected care diagnostics portfolio.
Digital Diagnostics’ management believes that the partnership with Baxter has the potential to significantly increase the number of patients benefiting from point-of-care diagnosis.
Industry Prospects
Per a report by Market Data Forecast, the global diabetic retinopathy market was valued at $7.45 billion in 2021 and is anticipated to reach $10.4 billion by 2026 at a CAGR of 6.9%. Factors like growing incidence of diabetes, increasing technological advancements in diabetic retinopathy surgical instruments and availability of favorable reimbursement for ophthalmologic surgeries are likely to drive the market.
Given the market potential, the latest collaboration is expected to significantly boost Baxter’s business worldwide.
Recent Developments
This month, Baxter announced new data indicating that the use of its Sharesource remote patient management platform with an automated peritoneal dialysis cycler may improve the clinical effectiveness of home kidney patients’ care by extending their time on therapy by 3.4 months.
Last month, Baxter received authorization from the Common Vulnerability and Exposures (“CVE”) program to be a CVE Numbering Authority. As a CVE Numbering Authority, Baxter is responsible for the assignment of CVE identifiers to cyber vulnerabilities for its own as well as Hill-Rom’s commercially available products, and for publicly disclosing information about the vulnerabilities in the associated CVE Record.
Also in February, Baxter announced its fourth-quarter 2021 financial results, wherein it registered a robust uptick in worldwide sales. The company also recorded solid performances across its three geographic segments, along with strong growth among its legacy businesses led by BioPharma Solutions.
Price Performance
Shares of the company have lost 2.3% in the past year compared with the industry’s 20% fall. The S&P 500 has risen 6.1% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Baxter carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Henry Schein, Inc. (HSIC - Free Report) , Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) and AMN Healthcare Services, Inc. (AMN - Free Report) .
Henry Schein, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average beat being 25.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Henry Schein has gained 23.4% compared with the industry’s 1.6% growth over the past year.
Allscripts has an estimated long-term growth rate of 16.3%. MDRX’s earnings surpassed estimates in the trailing four quarters, the average beat being 64.8%. It currently flaunts a Zacks Rank #1.
Allscripts has gained 33.3% against the industry’s 54.3% fall over the past year.
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average beat being 20%. It currently sports a Zacks Rank #1.
AMN Healthcare has gained 22.1% against the industry’s 61.3% fall over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Baxter (BAX) to Enhance Its Portfolio With Latest Partnership
Baxter International Inc. (BAX - Free Report) recently announced a long-term strategic partnership with Digital Diagnostics to advance diabetic retinopathy detection. The tie-up is aimed at helping front-line care providers deliver better quality of care and improve care outcomes.
It is worth mentioning that Baxter’s latest tie-up with the pioneering autonomous artificial intelligence (“AI”) diagnostics company includes plans to offer Digital Diagnostics’ IDx-DR autonomous AI software as a diagnostic service combined with the Welch Allyn RetinaVue 700 Imager (currently available for use in the United States). Notably, the agreement between Baxter and Digital Diagnostics is exclusive in the United States and non-exclusive outside.
The Welch Allyn product family became a part of Baxter's global medical technology portfolio following the latter’s acquisition of Hill-Rom in late 2021. The FDA clearance of IDx-DR with the RetinaVue 700 Imager is expected by early 2023.
The latest partnership is expected to significantly solidify Baxter’s global foothold in the connected care diagnostics portfolio.
Rationale Behind the Collaboration
Per current estimates (as mentioned in the press release), only around 15% of the diabetic patient pool receive the recommended annual diabetic eye exam. Also, access to effective diagnostic services is a hindrance, particularly in rural or underserved areas. This, in turn, leaves many with undiagnosed and untreated levels of disease, and a higher risk of consequent visual loss and blindness, as is recognized by the HEDIS/MIPS requirements for the diabetic eye exam. Hence, Digital Diagnostics created the autonomous AI diagnostic system — IDx-DR — for the detection of diabetic retinopathy (including diabetic macular edema) at the point of care.
Per Baxter’s management, the integration of AI within its devices is expected to provide a clear view of patient status to the primary care givers, thereby detecting information critical for treatment plans. The company believes that the partnership with Digital Diagnostics is integral in expanding its connected care diagnostics portfolio.
Digital Diagnostics’ management believes that the partnership with Baxter has the potential to significantly increase the number of patients benefiting from point-of-care diagnosis.
Industry Prospects
Per a report by Market Data Forecast, the global diabetic retinopathy market was valued at $7.45 billion in 2021 and is anticipated to reach $10.4 billion by 2026 at a CAGR of 6.9%. Factors like growing incidence of diabetes, increasing technological advancements in diabetic retinopathy surgical instruments and availability of favorable reimbursement for ophthalmologic surgeries are likely to drive the market.
Given the market potential, the latest collaboration is expected to significantly boost Baxter’s business worldwide.
Recent Developments
This month, Baxter announced new data indicating that the use of its Sharesource remote patient management platform with an automated peritoneal dialysis cycler may improve the clinical effectiveness of home kidney patients’ care by extending their time on therapy by 3.4 months.
Last month, Baxter received authorization from the Common Vulnerability and Exposures (“CVE”) program to be a CVE Numbering Authority. As a CVE Numbering Authority, Baxter is responsible for the assignment of CVE identifiers to cyber vulnerabilities for its own as well as Hill-Rom’s commercially available products, and for publicly disclosing information about the vulnerabilities in the associated CVE Record.
Also in February, Baxter announced its fourth-quarter 2021 financial results, wherein it registered a robust uptick in worldwide sales. The company also recorded solid performances across its three geographic segments, along with strong growth among its legacy businesses led by BioPharma Solutions.
Price Performance
Shares of the company have lost 2.3% in the past year compared with the industry’s 20% fall. The S&P 500 has risen 6.1% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Baxter carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Henry Schein, Inc. (HSIC - Free Report) , Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) and AMN Healthcare Services, Inc. (AMN - Free Report) .
Henry Schein, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average beat being 25.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Henry Schein has gained 23.4% compared with the industry’s 1.6% growth over the past year.
Allscripts has an estimated long-term growth rate of 16.3%. MDRX’s earnings surpassed estimates in the trailing four quarters, the average beat being 64.8%. It currently flaunts a Zacks Rank #1.
Allscripts has gained 33.3% against the industry’s 54.3% fall over the past year.
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average beat being 20%. It currently sports a Zacks Rank #1.
AMN Healthcare has gained 22.1% against the industry’s 61.3% fall over the past year.